Entrectinib OK'd for Cancers with Fusions, NSCLC.

The FDA has approved entrectinib for patients with any solid tumor bearing fusions, making it the second TRK inhibitor to receive a tissue-agnostic approval; larotrectinib was the first. How the drugs compare to each other remains unknown. Entrectinib was also approved to treat metastatic non-small cell lung cancer with rearrangements.